Oleh :IDH Mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617FPROGRAM STUDI BIOTEKNOLOGI, SEKOLAH PASCASARJANAUNIVERSITAS GADJAH MADAYOGYAKARTA2013

Background Primary MyelofibrosisSumsum TulangJAK2(70%), IDH, TET2. LNK, ASXL1, CBL

JAK2IDH

Material and MethodsSebanyak 301 pasien diikutsertakan dalam penelitianInformed written consent

Detection of JAK2, MPL, IDH1 and IDH2 Mutation

Dihitung berdasarkan pertama kali data diambil hingga kematian atau kontak terakhirDihitung berdasarkan pertama kali data diambil hingga leukemic transformation, kematian atau kontak terakhir

10 cmResult and Discussion

Figure 1 Overall survival data for 301 patients with primary myelofibrosis stratified by the presence or absence of IDH, MPL and JAK2 mutations.

Figure 2 Overall survival data for 301 patients with primary myelofibrosis stratified by the presence or absence of MPL, JAK2 or IDH mutations with or without concomitant JAK2V617F expression.

Figure 3 Leukemia-free survival data for 301 patients with primary myelofibrosis stratified by the presence or absence of IDH, MPL and JAK2 mutations.

Figure 4 Leukemia-free survival data for 301 patients with primary myelofibrosis stratified by the presence or absence of MPL, JAK2 or IDH mutations with or without concomitant JAK2V617F expression.

****